BLRX - バイオラインRx （BioLineRx Ltd.）

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securities and Exchange Commission (SEC) , “Penny stocks may trade infrequently – which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock should be prepared for the possibility that they may lose their whole investment.” Granted, a few good ideas do pop up that may be worth throwing a few dollars at. But more often than not, penny stocks can lead to heavy losses. So, I always ask that you never risk more than you can afford to lose. That being said, I’ve uncovered some hot biotech penny stocks you may want to toss a few dollars at. Atossa Therapeutics, Inc ( ATOS ) Source: Shutterstock At 75 cents, Atossa Therapeutics, Inc. (NASDAQ: ATOS ) is rebounding from support of around 65 cents.

BioLineRx Ltd. (NASDAQ:NASDAQ:BLRX) Q4 2022 Earnings Conference Call March 22, 2023 10:00 AM ETCompany ParticipantsJohn Lacey - Investor RelationsPhilip Serlin - Chief Executive OfficerMali…

Companies Reporting Before The Bell • Boyd Gaming (NYSE: BYD ) is estimated to report quarterly earnings at $1.09 per share on revenue of $848.27 million. • BurgerFi International (NASDAQ: BFI ) is projected to report quarterly loss at $0.22 per share on revenue of $44.90 million. • Travelzoo (NASDAQ: TZOO ) is projected to report quarterly earnings at $0.10 per share on revenue of $18.28 million. • Spectrum Pharmaceuticals (NASDAQ: SPPI ) is expected to report quarterly loss at $0.11 per share on revenue of $8.92 million. • CNFinance Hldgs (NYSE: CNF ) is likely to report earnings for its fourth quarter. • BioLine Rx (NASDAQ: BLRX ) is projected to report earnings for its fourth quarter. • LiqTech Intl (NASDAQ: LIQT ) is expected to report quarterly loss at $0.02 per share on revenue of $4.00 million. • Edible Garden (NASDAQ: EDBL ) is likely to report quarterly loss at $6.30 per share on revenue of $3.19 million. • Laser Photonics (NASDAQ: LASE ) is likely to report earnings for its fourth quarter. • EHang Holdings (NASDAQ: EH ) is projected to report earnings for its fourth quarter. • Petco Health and Wellness (NASDAQ: WOOF ) is projected to report quarterly earnings at $0.24 per share on revenue of $1.57 billion. • Zhihu (NYSE: ZH ) is likely to report quarterly loss at $0.09 per share on revenue of $154.77 million. • D-MARKET Electronic (NASDAQ: HEPS ) is estimated to report earnings for its fourth quarter. • Astria Therapeutics (NASDAQ: ATXS ) is likely to report earnings for its fourth quarter. • iMedia Brands (NASDAQ: IMBI ) is estimated to report quarterly loss …

biolinerx press release (BLRX): FY GAAP EPS of -$0.03 beats by $0.34.As of December 31, 2022, the Company had cash, cash equivalents, and short-term bank deposits of $51.1 million…

- Announced FDA Acceptance of APHEXDA (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M.D., as new Chief Medical Officer and Completed Formation of U.S….

BioLineRx Ltd. (NASDAQ:BLRX)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.95. At the close of trading, the stock’s price was $1.58, to imply an increase of 8.97% or $0.13 in intraday trading. The BLRX share’s 52-week high remains $3.62, putting it -129.11% down since that peak … BioLineRx Ltd. (NASDAQ: BLRX) Has Succeeded To Excite In 2022, The Stock Is Down -22.55% Year-To-Date Read More »

BioLineRx Tops Q1 EPS by 13c

biolinerx press release (BLRX): Q1 GAAP EPS of -$0.02.Ended the first quarter on solid financial footing, with cash and cash equivalents of $50.6 million, sufficient to fund…

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance - - Progressing critical Motixafortide pre-launch activities while maintaining full optionality on…

biolinerx (BLRX) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open.The consensus EPS Estimate is -$0.15 (-650.0% Y/Y) and the consensus…

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel, May 5, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the…

In last trading session, BioLineRx Ltd. (NASDAQ:BLRX) saw 0.52 million shares changing hands with its beta currently measuring 2.01. Company’s recent per share price level of $1.22 trading at -$0.04 or -3.17% at ring of the bell on the day assigns it a market valuation of $64.07M. That closing price of BLRX’s stock is at … BioLineRx Ltd. (NASDAQ:BLRX) Is Currently -419.67% Below Its 52-Week High, But Downside Potential Could Surprise You. Read More »

BioLineRx Earnings Beat, Revenue Inline In Q1

biolinerx press release (BLRX): FY GAAP EPS of -$0.04 beats by $0.42.CEO comment: "With over $57 million in cash, we believe we are well financed to extract maximum value…